Global Biosimilars Market to Soar to $24 Billion by 2019
New research from Frost & Sullivan reveals that the global biosimilars market earned revenue of about $1.2 billion in 2013 and could reach $24 billion in 2019.
New research from Frost & Sullivan reveals that the global biosimilars market earned revenue of about $1.2 billion in 2013 and could reach $24 billion in 2019.
The imminent entry of several companies, including Big Pharma, small biotech and generic participants, into the global biosimilars space will propel the market towards exponential growth, the report states. Already, Indian groups such as Dr. Reddy’s Laboratories, Biocon and Reliance Life Sciences are making a concerted effort to enter the European market; although they have not yet penetrated it due to the stringent regulatory pathway, new product launches are expected in the mid-term.
Biosimilar markets in countries such as the U.S. and Japan are also expected to grow exponentially with more clarity on the regulatory pathway, according to the report.
Untapped U.S. markets with a strong biosimilars pipeline as well as markets in Asia-Pacific and Latin America with a low cost of manufacturing will afford key growth opportunities.
“On one hand, the market is powering ahead regarding the strength of participants’ global expansion strategies, and, on the other, it is still beset by traditional patent-infringement issues,” said Frost & Sullivan Healthcare Senior Research Analyst K. Srinivas Sashidhar. “Moreover, the strategies adopted by innovator companies need to be taken into account. For instance, Johnson & Johnson has extended the European patent life of its innovator drug Remicade until February 2015, thereby delaying the launch of Hospira’s biosimilar monoclonal antibody (mAb) Inflectra and Celltrion’s biosimilar mAb Remsima.”
To further reduce the time to market, companies should also explore opportunities in mergers and acquisitions and alliances with companies having expertise in biosimilars manufacturing and development like Teva’s alliance with Cephalon and Lupin Pharmaceuticals’ alliance with Neuclone.
“In addition to mAbs, follitropins, interferons and low molecular weight heparins are likely to emerge in the long run,” added Sashidhar. “However, some companies may focus on specific therapeutic classes depending on their capabilities and strategic fit.”
For more information, visit http://www.lifesciences.frost.com
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
